ArticleClinical pharmacology and therapeutics2021
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Nicolas Frey et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.